Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
Pescovitz MD et al. | Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. | 2009 | Transplantation | pmid:19855247 |
Miroux C et al. | In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. | 2012 | Transplantation | pmid:22743548 |
Atkison PR et al. | Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. | 1997 | Transplantation | pmid:9311719 |
Gallon L et al. | ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. | 2006 | Transplantation | pmid:16477235 |
Niioka T et al. | Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. | 2012 | Transplantation | pmid:23073468 |
Aw MM et al. | Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. | 2003 | Transplantation | pmid:12660504 |
Veenhof H et al. | Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. | 2017 | Transplantation | pmid:27906832 |
Tourret J et al. | Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. | 2017 | Transplantation | pmid:27681266 |